Pod Insights Pharmacy Podcast Network Why the "SAFE Drugs Act" Isn't Safe for Patients | Essential: The Pharmacy Compounding Podcast About this episode In this episode, Andrew Kantor is joined by federal lobbyist David Pore and PCCA's Amy Shank to examine the proposed SAFE Act and its potential impact on compounding pharmacies. The discussion explores concerns that the bill could restrict patient access to compounded medications during drug shortages, impose new limitations on 503A pharmacies, and disproportionately affect legitimate compounders while failing to address bad actors. The episode also unpacks the legislation's connection to GLP-1 demand, adverse event reporting, and the bipartisan politics surrounding the bill, while encouraging listeners to stay engaged in APC's advocacy efforts.
Transcript 0:05 Speaker 00 You are listening to the global network of podcasters dedicated to the pharmacy profession. Welcome to the pharmacy podcast network.
0:25 Speaker 01 Welcome to Essential, compounding news and analysis from the Alliance for Pharmacy Compounding. I'm your host, Andrew Kantor. As usual, we're going to give you a bit of compounding news before we get to the main event. That's where we'll look at an anti-compounding bill now in Congress and how it could hurt patient access to essential, get it, compounded medications. But first, the news.
0:51 Speaker 01 So there has been some news on the peptides front. The FDA is considering a recommendation to add seven peptides to the 503A bulks list. And if you don't know what that is, it's a curated list the FDA is required to maintain of active ingredients that pharmacists are allowed to compound with, even though they aren't used in FDA-approved drugs. They don't have a monograph. A group of staff scientists at the FDA recommended that the agency not add those seven peptides to the 503A bulks list. But the most important recommendation is going to come later this month when the FDA's Pharmacy Compounding Advisory Committee,
1:30 Speaker 01 or PCAC, meets and considers the same question. PCAC, that doesn't sound right, like an angry duck. PCAC? Nah, PCAC. Anyway, here's a twist. PCAC's got some new members now, and they are health and wellness professionals who seem to have more patient-facing experience than the previous PCAC panels have. It's actually kind of refreshing, and maybe this new group won't just rubber stamp what the FDA tells it to. They might actually, you know, think about it. See, the thing is, it doesn't make sense to make a blanket rule covering every peptide. They aren't the same. There's nuance, and it'll do the agency good to have some voices that take... Take that into account. We're not going to get into the weeds when it comes to which
2:13 Speaker 01 peptides have safety studies, which are effective, which ones are probably just hype. We're well aware that some of these peptides have really limited safety data. And yeah, safety is everyone's priority. Well, maybe not everyone's, but yeah. The point is, the FDA shouldn't be thinking about this as a binary choice. It's not approve all the peptides versus ban all the peptides. Nuance. If nothing else, the agency can't ignore the fact that there's already a flourishing gray market out there. It's an entire peptide economy, and it's not safe. And just saying, we need more enforcement, which is what the FDA has been doing. That's not a strategy. It's a soundbite. What we need, and hopefully what
2:53 Speaker 01 this new PECAC will recommend, is smart guardrails. We're talking quality expectations, API controls, documentation, all the rules that will allow some peptides to be added, safely, to the bulks list. So patients can get them through legitimate licensed compounding pharmacies, rather than some rando on TikTok or Instagram, because that's what they're doing right now. We need to go from this illicit market for peptides, I mean, talk about the Wild West, to the, the opposite of the Wild West, a smartly regulated alternative, one that's not a threat to patient's safety, not a ban that throws the baby out with the bathwater. The alternative, whether we like it or not, is patients turning to these unregulated,
3:36 Speaker 01 unsafe, fly-by-night peptides R Us shops, and then crossing their fingers that what they get in the plain brown wrapper, it's not just baking soda and baby powder. Worse, that's not patient's safety. PECAC and the FDA can do better. Here's hoping they do. Last month, the Supreme Court let stand a ruling from the Fifth Circuit Court of Appeals. It's a ruling that allows drug makers to sue compounders by claiming that compounding violates state deceptive practices laws. Until this happened, it was only the FDA that could bring a pharmacy to court if it thought the Food, Drug and Cosmetic Act had been violated. The ruling, or the lack of one, is a problem, and not just because
4:20 Speaker 01 At least to us, it doesn't quite make sense. It leaves us with what's called a circuit split. Right now, in the Fifth Circuit, and it's Louisiana, Mississippi, and Texas, private parties, not just the FDA now, can challenge whether a compounded product complies with federal requirements, and they can do it in state court. So a drug maker, a private organization, can sue a pharmacy claiming that it's breaking the FDNC Act. But in the Ninth Circuit, and that includes all the western states from Alaska, California, down to Hawaii, Idaho, a bunch more. In the Ninth Circuit, the appeals court there ruled the opposite, that only the FDA can enforce federal law. The practical outcome, at least until the Supreme Court takes up another case,
5:05 Speaker 01 is that compounders in some states may have to defend themselves against drug makers who use state laws to challenge legal compounding. And that is APC's big concern. If some states can restrict compounding beyond what Congress obviously intended, well, that throws the entire compounding industry into confusion. It's dueling standards, and nobody wins.
5:29 Speaker 01 We've got good news and bad news out of California, where an anti-compounding bill, AB 1990, passed the state assembly and is now in the state senate. After a lot of pressure from APC and the coalition we led, the assembly sponsor took out just about all the problematic language. But "just about" isn't the same as "all", and there are some serious issues still in the bill. This new version of AB 1990 focuses on how compounders can advertise and promote their products. And that might not seem like a big deal, but it's got a couple of problems. For starters, for a bill that's supposed to be about patient safety, it doesn't do a thing to protect consumers from the real problem, and that's the counterfeit sellers, the unlicensed clinics,
6:12 Speaker 01 and the places that are selling consumers' research-grade products. Instead, AB 1990 focuses on legitimate licensed compounding pharmacies, the places that are already highly regulated by both the feds and state law. And it includes some new requirements that are actually... Illegal or impossible. Uh, here's an example. AB 1990 would require compounding pharmacies to include risk information with their products. Risk information that they are supposed to take from the labels of the commercial drugs. But the compounded drug isn't the commercial drug. You can't copy and paste warnings from one to the other. It's not only misleading, it is illegal by federal law. So you see why the bill's a problem.
6:56 Speaker 01 Right now, California Senate is in recess, but come August, it's going to hear the bill. And that means if you're in California, you do not have a lot of time to reach out to your state senator and explain why AB 1990 is such a problem, and it really won't do anything to help patients. Heck, by forcing compounders to choose between obeying state law and obeying federal law, it could cut patients off from their compounded meds completely and force them into the gray market. There's a link in the show notes that makes it easy to send a message to your state senator, so please, use it. Finally, back in Washington, there's still the Safeguarding Americans from Fraudulent
7:37 Speaker 01 and Experimental Drugs Act, the Safe Drugs Act, which is gaining some steam. And that's because it's being pushed hard by drug makers, and it would severely limit compounding pharmacists from preparing copies of commercial FDA-approved drugs, even if those drugs are in shortage. In other words, if a drug goes into shortage, say if there's another pandemic, or just another manufacturing hiccup, the SAFE Act would only allow compounders to make 20 copies of it for patients each month. That's right. No matter how critical the drug is, how many patients rely on it, the SAFE Act would put a flat arbitrary cap on compounding it, completely ignoring that the drug shortage list exists.
8:21 Speaker 01 Now, think about what that would mean for patients, because it's probably the something the drug makers conveniently forgot to mention when they meet with legislators. That's why we've been urging our members to come to Compounders on Capitol Hill. That is our annual event in Washington, where we meet face-to-face with the very legislators who these Pharma companies are trying to fool. It is the best way, bar none, to get our message across and to explain to these representatives and senators why pharmacy compounding means so much to their constituents, especially during a drug shortage. Uh, the good thing is, if you come to compounders on Capitol Hill, you don't need any lobbying experience at all. You're never on your own.
9:02 Speaker 01 We schedule the meetings, we brief you on the issues, and we have lobbyists with you in every office you go to. Compounders on Capitol Hill, it's our most important event of the year, and if you're a compounding pharmacist or a technician, we really hope you'll come to DC on September 14th through the 16th. Obviously, there's a link in the show notes to get all the information you need. And with that, it is time for our deep dive, and it is all about this troublesome bill. Today, we're going to talk about a bill in Congress that's kind of an anti-compounding bill. It's called the Safeguarding Americans from Fraudulent and Experimental Drugs Act, the
9:47 Speaker 01 SAFE Act. And it's a bit controversial, to say the least. With me are two people who know all about it and a lot more. First is David Poor. He's an attorney and partner with Hans Scarborough in Washington DC, and also APC's federal lobbyist. And with David is Amy Shank, and she's Senior Director for Government and Public Affairs at PCCA. Welcome, both of you.
10:11 Speaker 02 Good morning.
10:11 Speaker 03 Thank you. And good morning.
10:12 Speaker 01 We'll start with the basics, and I'm going to try to keep everything in plain English. What does this SAFE Act actually do, in broad strokes? I mean, how would it change how a compounding pharmacy operates day to day?
10:26 Speaker 03 Yeah, I'll jump in, Andrew. So, you know, I think we could start with the title and what the bill does not do, and that is have anything to do with fraudulent or experimental drugs. So, we really, starting with the title, we take issue with a lot in this bill and the way it's being messaged and the way it's being lobbied and described on Capitol Hill. Basically, what the drug would do... Is change the dynamic around 503A compounding and would effectively override or preempt the current FDA guidance on compounding drug products that are essentially copies of commercially available drugs. So drug shortage compounding would be dramatically
11:10 Speaker 03 changed because the bill would codify some new definitions into law of what essentially a copy and commercially available mean. And to really cut to the chase, what it would do is remove the current exemption from the definition of commercially available drugs, drugs that are on FDA's drug shortage list. And so currently, there are two situations when compounding essentially a copy of an FDA-approved drug is allowed. Once, one, when the drug is in shortage, when FDA has determined that there's a drug shortage and that drug is
11:49 Speaker 03 on FDA shortage list. And two, when a significant difference is made to the drug to meet the specific needs of an individual patient. And this could be route of administration, dosage form, strength, these kinds of changes that are needed to to make the drug tailored to meet a specific patient's needs. And this bill, along with a few other things, some reporting requirements and some new requirements on 503B, outsourcing facilities. The most onerous provision in this bill is ending the ability of 503A pharmacies to compound drugs on the drug shortage list.
12:32 Speaker 03 And I can get into some more detail on that as we go along.
12:35 Speaker 01 For those folks listening who don't know the difference between 503A and 503B compounding, and correct me if I'm wrong, 503A is your small, usually a neighborhood pharmacy, maybe it's got several locations, but it's it's a small individual pharmacy. They get a prescription for a single patient and fill the prescription with a compounded medication, one on one. Whereas 503Bs are the larger outsourcing facilities that compound many more drugs that are then
13:11 Speaker 01 Either shipped to 503As or to hospitals or in other cases where it's not just a single individual involved. Is that right?
13:21 Speaker 03 Yeah, that's right, Andrew. 503As refer to traditional state licensed pharmacies, which you would think of as your neighborhood pharmacy. In a lot of cases, they're required to compound drugs on a patient-specific basis pursuant to a patient-specific prescription. They do so subject to state laws and state regulatory frameworks over pharmacy. And in almost all cases, states require that those drugs are compounded pursuant to US Pharmacopeia standards, USP standards. Whereas outsourcing facilities are registered with FDA, they are held to a higher CGMP, Current Good Manufacturing Practices, standards,
14:03 Speaker 03 and are able to compound in larger volumes, as you said, without patient-specific prescriptions for hospitals, doctors, clinics, or for sale to 503A pharmacies for dispensing.
14:15 Speaker 02 Yeah, that's great, David. I would just add that the 503A pharmacies are compounding typically both either non-sterile medications, so think capsules, creams, and then also the sterile medications such as eye drops or injections, whereas the 503B outsourcing facilities are required to produce sterile medications. So maybe they might also produce the capsules and the creams, but they're required to produce sterile medications.
14:44 Speaker 01 And what we learned during, well, the GLP-1 shortage, semaglutide terzepatide shortage, was that the 503As, the smaller, the individual pharmacies stepped in and were able to provide these drugs. So it was kind of important that they were there during shortages. And certainly during the pandemic, we talked a lot, we've heard a lot about 503Bs during the pandemic, but 503A pharmacies were also stepping up because drugs were in shortage. And now you're saying the SAFE Act is going to not allow them to do compounding when drugs are in shortage? It seems kind of a big deal.
15:29 Speaker 03 It is a big deal, Andrew, and you know, you just hit the nail on the head. During the pandemic pharmacies, both 503B pharmacies, in some cases, outsourcing facilities were compounding shortage drugs. But what we found is that because the outsourcing facilities are subject to CGMP requirements that include testing requirements and compounding of large batches of drugs and kind of a ramp up and ramp down period, they're not as nimble as the 503A pharmacies in responding to drug shortages. That's why the 503As were able to quickly step in and compound COVID drugs that had gone into shortage and through an emergency guidance during COVID, were actually able
16:12 Speaker 03 to do so prior to receipt of a patient's specific prescription. So yes, pharmacies played a critical role in addressing the pandemic when we were going through that.
16:23 Speaker 02 And it was quite a variety of drugs too, right, David? So it was everything from the drugs used to intubate patients that were allowed by the guidance. And then it was also just, all shortages are probably unexpected, most are, but hydroxychloroquine went into shortage and that left many autoimmune patients who'd relied on the therapy sometimes for many, many years without their medication and then needing to turn to compounded alternatives when they couldn't, they couldn't get it through regular channels. So a lot of different angles to how compounding helped patients significantly during COVID.
17:02 Speaker 03 Yeah, and that's still the case, Andrew. I mean, at any given time, you've got 80 to 90 drugs on FDA shortage list. They come on and go off as FDA determines their availability. But right now, you've got, you know, a lot of cancer drugs, several hospitals, sterile injectable drugs, lidocaine and other sterile injectables that hospitals need that are in shortage. So this is a lot broader and a lot, a lot more serious than just GLP-1 drugs.
17:34 Speaker 01 Well, I'll get to GLP-1s in a second. As I understand it, and again, correct me if I'm wrong, the impetus for this bill is that, well, in part, big drug makers are saying that there are a lot of adverse event reports with compounded drugs and other kind of...
17:56 Speaker 01 Issues, but specifically adverse event reports. So someone says that a compounded drug did something bad to them, whatever it is, it's an adverse event. It could be big, could be small. But as I understand it, these adverse event reports that the big drug makers point to and and have been pushing because been pushing, leading to this bill, they're problematic. It's not like this is some kind of detailed official document of issues with compounded meds. Is that right? They're kind of misleading, these adverse events reports.
18:37 Speaker 03 Yeah, it's complicated. But basically, yes, these are reports that an adverse event has occurred. Somebody took a compounded drug and called into the FAERS system, the federal adverse event reporting system. But what it lacks is any sort of follow up, any sort of investigation as to causation of the adverse event. So yes, an adverse event got reported after somebody took a drug, but no medical evidence that the adverse event was caused by the compounded drug and not perhaps by some sort of, you know, user error. Maybe the patient took, made a mistake in taking the drug. Maybe it was an allergic reaction. Maybe it was something entirely different that had nothing to do with the
19:21 Speaker 03 compounded drug. So it's a little misleading to report adverse events tied to compounded drugs without that evidence of some sort of link to the compounded drug and investigation of causation. And the problem exists on the FDA approved side as well. I mean, the same thing until there's an investigation as to what caused the adverse event. It's misleading to just state the statistics on the number of reports without knowing whether those are valid reports actually tied to something related to the compounded drug.
19:54 Speaker 01 Well, it also seems that you get adverse events with, I'll call them, commercial drugs, FDA approved drugs, the big manufacturers drugs, not just compounded versions. Is that the case? Because no one seems to mention how many adverse events there are with, you know, brand name drugs. Is that because there aren't adverse events?
20:20 Speaker 03 Yes, there are, you know, many adverse events reported from FDA-approved drugs. In fact, the numbers are comparable when you break it down and you look at it. But again, the same problem exists. We don't know if those adverse event reports on the FDA side are necessarily because of the FDA-approved product the patient took. So it's an imperfect system, the reporting system. And really, you know, those, those numbers and those statistics can be used to mislead policymakers and the public. And that's, that's unfortunate, and that's some of what's going on here.
20:49 Speaker 01 So we, we know that, that compounding is really important during shortages. And this bill is going to severely limit the ability for compounders to supply drugs to patients. The, the bill comes out of two representatives from Indiana and one from each side of the aisle, which is, you know, these days is kind of odd on its face. But why is that happening? Why are they introducing a bill that is gonna, well, it's, it's gonna hurt patients. It's gonna prevent them from getting drugs that are in shortage. What's, why do we have this, this purple bill for compounded drugs?
21:31 Speaker 02 So, you know, it's, it's interesting. We have, have always looked at this through the lens of it's about patients. And what can we be doing to make sure that patients have access to their medications? And haven't really looked at it so much as a Republican issue or a Democrat issue. Because certainly there are patients who are both, right? There are Republican patients and there are Democrat patients. So just really focusing on patient-centered policy is what we've tried to, to work toward. Yeah, it's interesting. In this year, the second half of the year, there's going to be probably a full two months
22:13 Speaker 02 when the, many of the lawmakers are back in their states and districts. Pretty much the, most of the month of August. And then similarly, the month of October. And in terms of an educational drive, certainly it's
22:29 Speaker 02 Helpful time to invite lawmakers to come out and tour a compounding pharmacy, right? It's really different than a retail setting. It's very different to gown them back, to take them back in the lab and to let them see what is there. Now, I hope that that happens and that we have many compounding pharmacists who are doing that and showing their facility. But what's really key, and what you touched on, what we talked about earlier, was the impact on the patients and those site visits. It's really key to have patients there attending. So the patients can then speak up and explain what type of medicine are they on? Why was it prescribed for them? What's their experience been like?
23:10 Speaker 02 And to have that different perspective brought into the site visit where you can hear from the pharmacist about how these medications are custom-made for the patient, you can hear from the patient about why they're needed, because it really is about patient-centered policy. And we've tried to not really look at this so much as a partisan issue.
23:34 Speaker 03 Yeah, I think that's right, Amy. I mean, we have Republicans and Democrats that are very supportive of compounding, pharmacy compounding, and we've got Republicans and Democrats that are very close to the pharmaceutical industry and really buy into some of the patient safety arguments being made. And that's really where the lobbying on the other side, the lobbying in support of this bill, has been focused. And, you know, I mentioned it at the beginning of the podcast, that it starts with the name. When you put fraudulent, you know, saving Americans from fraudulent and experimental drugs, who doesn't want to save Americans from fraudulent and experimental drugs? And so when you start with a title like that and you're saying that a member of Congress,
24:15 Speaker 03 their constituents are in danger of risky compounding and that this drug is going to, this bill is going to somehow improve that situation, that becomes a persuasive argument in getting members of Congress, especially those that may not have deep policy experience or serve on the committees of jurisdiction that this type of legislation would go through. You know, normally, when you get a healthcare bill... Dealing with pharmacy or other healthcare policy, you would take it to a member of the Energy and Commerce Committee where this type of legislation would go in the House, or a member of the Health Committee in the Senate. The two original sponsors of this bill in the House both come from a state that is
24:59 Speaker 03 where the headquarters of one of the major pharmaceutical companies that manufacture GLP-1s are located. And so, you know, what we've seen is persuasive arguments that there's somehow a large patient safety risk out there that makes it necessary to restrict compounding. And in this case, you know, it's very focused on drug shortage compounding. And so, the actual substance of the bill doesn't have a lot to do with improving patient safety. It has to do with protecting the market share of the pharmaceutical companies that make the drugs that are going into shortage. And so, that's our issue with it. But when you kind of peel those layers back, and as we talk to members of Congress and
25:43 Speaker 03 educate them about the bill, what we're finding is that there's been a lot of misinformation surrounding this bill. And some of the members of Congress, even those that have co-sponsored the bill, are unaware that it would codify a definition of commercially available that would radically change the current framework of drug shortages and how we as a country address drug shortages. And part of that system involves compounding when those drugs are on the FDA shortage list. So, it's been interesting to see that there are members of Congress that were not informed that that's what the bill does and are being told that it's all about protecting patient safety.
26:24 Speaker 03 But there's really, you know, what they're leaving out is that if you're creating a situation where drugs are in shortage and there's no legal pathway for compounding pharmacies to step in and help address those shortages, you're actually creating a patient safety issue, not addressing one. And that's how we look at this bill.
26:45 Speaker 02 That's right, because lack of access is a patient safety issue.
26:49 Speaker 01 So realistically, if this bill passes, what are patients going to see? Are there going to be any benefits to patients? And what is, what's the kind of thing that your average Joe who needs a compounded medication? What are they going to see? And what are patients in general going to see after it passes?
27:09 Speaker 03 Well, one of the things that concerns us is, is the, the hard cap. The bill contains a cap. So once, once you remove the exemption for drugs on the FDA shortage list from the definition of commercially available, and you codify this prohibition on compounding those drugs, and you put into the statute an arbitrary limit of no more than 20 drugs compounded that are essential copies. What you create is a situation where if, if a drug is on the shortage list, there's not an outsourcing facility that's able to react quick enough to get those drugs compounded into the providers and patients that need them.
27:50 Speaker 03 Pharmacies will be limited, capped at 20, 20 copies per month. And so that is a very arbitrary cap that kind of removes the current language and the guidance that is much more subjective, much more enforcement discretion based, and is really based on quantities needed to address unanticipated emergency circumstances.
28:13 Speaker 01 So, well, hold on one second. Are you saying that this 20 prescriptions a month limit, meaning each pharmacy can say, okay, well, 20 patients, I can take care of and give you access to this drug that's in shortage. The rest of you, sorry?
28:28 Speaker 02 Yeah, you have to figure out what you're going to say to the 21st patient or the 25th patient. And, you know, in particularly in rural areas, it's your neighbor, a family member, someone that you've helped for a while. How do you choose who gets their medicine and who doesn't get their medicine? It's very troubling. And it's, you know, peeling an onion, the further you get into it, the more complicated it becomes, right? So when the industry started to, to vet this more thoroughly earlier in the year, it just, it became obvious that, that it's, it is, uh, there's a lot of layers to it and it's complicated. And the Alliance for Pharmacy Compounding, and then also the National Community Pharmacists Association.
29:10 Speaker 02 That's a letter explaining their concerns with the proposal and strong opposition to members of Congress, and it's a helpful letter. It's on the APC website, but it just really breaks down some of the complicated issues that David has articulated on this podcast today and just cuts to the chase in terms of where the concerns truly lie. So that letter, I think, in addition to the educational outreach, is a terrific tool to really highlight the concerns and the access gaps that would exist.
29:46 Speaker 01 And we'll have a link to that letter in the show notes. I want to, we've been avoiding mostly talking about GLP-1 drugs specifically because this bill is going to affect more than that. But the bill is positioned as being about compounding in general and making it quote unquote "safe." And as we said, that's not really true. But how much is really about GLP-1 compounding? Because that was in the news, is still in the news with the
30:23 Speaker 01 shortages of Ozempic and Zepbound and their kin. Because it's not a coincidence that this bill comes up just as these blockbuster drugs are sort of kind of coming out of shortage.
30:38 Speaker 03 Yeah, and anybody with a television, Andrew, remembers, you know, and still sees just kind of on a loop, the commercials, the heavy, heavy marketing for the FDA-approved products in this GLP-1 space. And really, the kind of the boom, the boom in prescriptions as these drugs started to get prescribed for weight loss and not just other medical indications like diabetes and others, you really saw just aggressive marketing that led to drug shortages. The manufacturers were not able to keep up with the demand. Those drugs went into shortage, the 503 outsourcing, 503b outsourcing facilities.
31:19 Speaker 03 Again, have their own limitations due to CGMP requirements that make it difficult for them to start and stop drug shortage compounding. They're not nearly as nimble as the 503A pharmacies. And so, yes, I think the impetus behind the bill was the manufacturers seeing that 503A pharmacies were able to step into this space, compound essential copies that were safe and effective, and in a lot of cases at a much lower cost. And that's not a reason that FDA recognizes as a legitimate reason that makes a significant difference for a patient. We could argue about whether pricing should be included in that, but it's
32:04 Speaker 03 not under the current guidance. And so frankly, they didn't like the competition is how I see it, and really have aggressively since then gone after pharmacies. Now, another nuance here is the provision in the current guidance that allows for compounding essential copies of FDA-approved products if a significant difference is made to the drug product for an individual patient. And so this has led to some pharmacies compounding drugs that are in different dosage forms or routes of administration or strengths to meet individual
32:44 Speaker 03 patient needs that has led to allegations of copying and pretext use of different dosage forms and things that violate the spirit of the guidance. So there's a gray area there and room for discussion about what a true significant difference to an individual patient looks like. But right now, the guidance and the framework around drug shortage compounding is working and protecting patient access, whereas this bill would would end that drug shortage and replace drug shortage compounding, replace it with the arbitrary 20 cap.
33:24 Speaker 01 So it just seems to me you've got this gray area, as you say. And the reaction, I mean, for me, if you have a gray area that needs to be quote unquote "fixed," you target a bill at that gray area, you tweak existing legislation. But here, I mean, there are bad actors out there, but it seems like this bill is throwing the baby out with the bathwater and painting with broad strokes and potentially hurting a lot of patients when it's trying to solve essentially a small problem with this gray area can't be that big.
34:03 Speaker 03 Yeah, Andrew, I think there would be ways to go in much more surgically and address this idea of what is a true significant difference and maybe building on the existing language and the guidance. But you're absolutely right, that they're throwing the baby out with the bathwater here by eliminating all compounding of drugs on the drug shortage list, subject to the 20 per pharmacy cap per month. And so, yeah, it's not, it's not the ideal system and it's not going to improve patient access.
34:39 Speaker 01 Amy?
34:40 Speaker 02 Yeah, I think that's a very well said is that certainly there's, there's significant access concerns with the proposal. I do point back to the association letter from April in terms of a very helpful summary of walking through issue by issue where the concerns are and hope that, you know, we can just keep working with anyone who is interested in, you know, patient-centered policies. That's what's really driving us and just to make sure that patients can get the medicine they need.
35:23 Speaker 01 Right. Well, thank you. Thank you both for taking the time to join us today. I know you're both really busy. And this is, in some senses, it's a complicated issue, but in another sense, it feels like it's pretty straightforward. A lot of people are going to lose access to drugs that are in shortage that could have been given to them via compounding pharmacy if this passes. And you've mentioned a couple of times the the letter from NCPA, which we will link to. But this is an issue that's going to affect a lot more people, I think, than folks, certainly folks in Congress realize.
36:05 Speaker 03 I think that's right, Andrew. Yeah. And, you know, right now, we're we're not seeing the bill move in this Congress, luckily, but we're really looking ahead to the next Congress and the possibility that it could get some traction. And so we're trying to make the rounds and educate folks about what it does. It does not do.
36:22 Speaker 02 I gotta say, that's one thing too, APC's done a great job about is just overall engagement and patient engagement as well on their website, noncompounding.com, and just, you know, pushing out these messages and points of concern. I feel remiss without mentioning before we wrap up that their legislative conference, Compounders on Capitol Hill, is right around the corner. And it really is a terrific opportunity for compounding pharmacists to come to Washington and just explain the needs of their patients, number one, and then, number two, the concerns
37:05 Speaker 02 about the legislative proposal. And sometimes I like to think of them as the law of unintended consequences, right? So that's September 14 through the 16 here in Washington. And I think that APC just opened registration for that.
37:20 Speaker 03 That's a great plug, Amy. Thank you so much for that wonderful plug. Yeah, and this bill will definitely be one of the top policy issues that we'll be talking about on Capitol Hill. So really encourage everybody listening to sign up and come join us at Compounders on Capitol Hill.
37:33 Speaker 02 And we will both be there.
37:35 Speaker 01 If you are a compounding pharmacist or work with them, yeah, Compounders on Capitol Hill, there'll be a link to that in the show notes also. And if you're a patient and you're getting compounded drugs or a drug you take is in shortage, talk to your pharmacist and talk to your legislator and say, hey, this is going to cut me off because they don't always know what's happening on the ground with with real patients, especially if they're getting, David, as you pointed out, a lot of misinformation from some of the bigger players. So again, thank you. Thank you both for being here. Really appreciate it. And, and that is it for this episode of Essential. But before
38:17 Speaker 01 we hit that outro music, I always point this out, if you are a compounding pharmacist or technician, or if you prescribe compounded meds, not only should you come to Compounders on Capitol Hill, but remember that APC is here helping you and helping your patients. I won't go through everything that APC does, but we are the biggest and the loudest trade association for the compounding profession. So if you're not a member, we would love you to become one. We are working for you. So come on board. Just head over to a4pc.org, check out what we're doing. All right, Brady, play that outro music now. Thanks, everyone for listening.
Previous Insights Beyond the Counter Episode 1 | Outcomes: Insights Beyond the Counter Next The 2026 McKesson ideaShare Rewind | Part Three Page updated November 14, 2026 · transcript and summary are machine-generated